Editorial commentary: Turning the tide on HIV in women and children: Preventing breast-milk HIV transmission while increasing maternal life expectancy

Clinical Infectious Diseases

Volumn 56, Issue 1, 2013, Pages 140-142

  Becquet, Renaud ^a,b   Dabis, François ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

antiretrovirals; breast milk; HIV; mother to child transmission

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; RITONAVIR;

BREAST MILK; CD4 LYMPHOCYTE COUNT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTATION; LIFE EXPECTANCY; MATERNAL LIFE EXPECTANCY; NOTE; PREGNANT WOMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SOUTH AFRICA; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

EID: 84871188196     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis813     Document Type: Note

References (20)

1. UNAIDS. Together we will end AIDS. 2012. Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/ 20120718-togetherwewillendaids-en.pdf. Accessed 16 August 2012.
2. Becquet R, Marston M, Dabis F, Moulton LH, Gray G, Coovadia HM, et al. Children who acquire HIV infection perinatally are at higher risk of early death than those acquiring infection through breastmilk: a metaanalysis. PLoS One 2012; 7:e28510.
3. Mushavi A. Strategies for identifying HIVexposed infants. (Satellite session: Prevention of vertical transmission and beyond: how to identify, enroll and retain children in treatment programmes in resource-limited settings.) In: 19th International AIDS Conference; July 22-27 2012; Washington, DC. Available at: http://pag.aids2012.org/session. aspx?s=21#3. Accessed 25 September 2012.
4. World Health Organization. Recommendations for use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: guidelines on care, treatment and support for women living with HIV/AIDS and their children in resource-constrained settings. 2010.Available at: http://www.who.int/hiv/pub/mtct/guide lines/en/. Accessed 16 August 2012.
5. Becquet R, Ekouevi DK, Arrive E, Stringer J, Meda N, Chaix ML, et al. Universal antiretroviral therapy for pregnant and breastfeeding HIV-infected women: towards the elimination of mother-to-child transmission of HIV-1 in resource-limited settings. Clin Infect Dis 2009; 49:1936-45.
6. Mofenson LM. Antiretroviral drugs to prevent breastfeeding HIV transmission. Antivir Ther 2010; 15:537-53.
7. Hudgens M. Pooled individual data analysis of five randomized trials of infant nevirapine prophylaxis to prevent breast-milk HIV-1 transmission. Clin Infect Dis 2012; XX:20-30.
8. French National Agency for Research on AIDS and Viral Hepatitis. Comparison of Efficacy and Safety of Infant Peri-exposure ProphylaxisWith Lopinavir/RitonavirVersus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding. Available at: http://www. clinicaltrials.gov/ct2/show/ NCT00640263? termppromise-pep&rankp1. Accessed 25 September 2012.
9. Hargrove J, Humphrey J, Zvitambo study group. Mortality among HIV-positive postpartum women with high CD4 cell counts in Zimbabwe. AIDS 2010; 24:F11-4.
10. Jamieson DJ, Chasela CS, Hudgens MG, King CC, Kourtis AP, Kayira D, et al. Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial. Lancet 2012; 379:2449-58.
11. Maman D, Pujades-Rodriguez M, Nicholas S, et al. Response to antiretroviral therapy: improved survival associated with CD4 above 500 cells/μl. AIDS 2012; 26:1393-8.
12. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
13. World Health Organization. Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Programmatic update, 2012. Available at: http://whqlibdoc.who.int/hq/2012/WHO-HIV-2012.6-eng.pdf. Accessed 16 August 2012.
14. Kesho Bora Study Group. Maternal HIV-1 disease progression 18-24 months postdelivery according to antiretroviral prophylaxis regimen (triple-antiretroviral prophylaxis during pregnancy and breastfeeding vs zidovudine/single-dose nevirapine prophylaxis): the Kesho Bora randomized controlled trial. Clin Infect Dis 2012; 55:449-60.
15. Ezeh AC, Bongaarts J, Mberu B. Global population trends and policy options. Lancet. 2012; 380:142-8.
16. Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS1269 trial): a randomised trial. Lancet 2006; 367:1981-9.
17. El-Sadr WM, Grund B, Neuhaus J, et al. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med 2008; 149:289-99.
18. Luo C. Turning the tide for children and youth. (Plenary session: Turning the tide on transmission). In: 19th International AIDS Conference; July 22-27 2012; Washnigton, DC. Available at: http://pag.aids2012. org/session.aspx?s= 678#2. Accessed 25 September 2012.
19. Schouten EJ, Jahn A, Midiani D, et al. Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet 2011; 378:282-4.
20. Schouten E. Beyond Option B: discussion of B+ and other alternatives to pre-natal and neonatal prophylaxis. (Satellite session: Prevention of vertical transmission and beyond: how to identify, enroll and retain children in treatment programmes in resource-limited settings). In: 19th International AIDS Conference; 22-27 July 2012; Washington, DC. Available at: http://pag.aids2012. org/session.aspx? s=21#3. Accessed 25 September 2012.